Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Saved in:
Similar Items
-
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Oren Pasvolsky, et al.
Published: (2025-05-01) -
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Danai Dima, et al.
Published: (2025-06-01) -
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
by: Danai Dima, et al.
Published: (2025-07-01) -
Soil Carbon Remote Sensing: A Meta-Analysis and Systematic Review of Published Results from 1969–2022
by: Savannah L. McGuirk, et al.
Published: (2025-05-01) -
BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
by: Mahmoud R. Gaballa, et al.
Published: (2025-03-01)